{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:13:50Z","timestamp":1777320830344,"version":"3.51.4"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Philadelphia (Ph)-negative myeloproliferative neoplasms can exhibit defects in Janus kinase 2 (JAK2), Calreticulin (CalR), and MPL genes. It is possible that the presence of other driver mutations may influence diagnosis and prognosis in patients who do not have a JAK2 gene mutation. The purpose of this study was to assess the frequency of CalR and MPL gene mutations and the clinical effects of these mutations in JAK2 gene-unmutated MPN patients from a single center. Materials and Methods: We examined 46 patients (ET\/PMF: 34\/12) diagnosed with MPNs regarding their genetic conditions, diagnoses, and complications. Results: CalR Type 1 gene mutation was detected in 26.1% of cases, CalR Type 2 gene mutation in 13.0%, MPL-L gene mutation in 2.2%, and MPL-K gene mutation in 6.5%. In total, 56.5% of patients were triple-negative. The presence of CalR Type 1 and Type 2 mutations was significantly more prevalent in patients with essential thrombocytosis (ET), although the difference did not reach statistical significance (p = 0.51, p = 0.57). In contrast, MPL mutations were only observed in patients with primary myelofibrosis (PMF). Conclusions: We found no correlation between thrombosis, leukemic transformation, and driver mutations. MPL gene mutation was present in only myelofibrosis patients, and CALR gene mutation was present in one of the three cases of leukemic transformation. The triple-negative group had a lower survival rate, but this difference was not statistically significant (110.3 months vs. 121.4 months, respectively, p = 0.53). However, the sample size was quite small. Our limited observations suggest a possible trend that requires confirmation.<\/jats:p>","DOI":"10.3390\/medicina61060962","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:35:09Z","timestamp":1747982109000},"page":"962","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study"],"prefix":"10.3390","volume":"61","author":[{"given":"Tar\u0131k Onur","family":"Tiryaki","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul 34134, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-0646","authenticated-orcid":false,"given":"Aynur","family":"Da\u011flar Aday","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Medical Genetics, Istanbul University, Istanbul 34134, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-5024","authenticated-orcid":false,"given":"Meliha","family":"Nal\u00e7ac\u0131","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul 34134, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akif Selim","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul 34134, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some Speculations on the Myeloproliferative Syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Baumeister, J., Chatain, N., Sofias, A.M., Lammers, T., and Koschmieder, S. (2021). Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells, 10.","DOI":"10.3390\/cells10123551"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European Leukemia Net","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: Primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"047","DOI":"10.1055\/s-0040-1701474","article-title":"How I Manage Thrombotic\/Thromboembolic Complications in Myeloproliferative Neoplasms","volume":"40","author":"Koschmieder","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): Analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jcp-2023-208861","article-title":"High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants","volume":"77","author":"Sande","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Paz","year":"2023","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential Thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.2023023428","article-title":"CALR mutation burden in essential thrombocythemia and disease outcome","volume":"143","author":"Guglielmelli","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International Consensus Classification of myeloid and lymphoid neoplasms: Myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2360246","DOI":"10.1080\/16078454.2024.2360246","article-title":"The characteristics of CALR mutations in myeloproliferative neoplasms: A clinical experience from a tertiary care center in Qatar and a literature review","volume":"29","author":"Najim","year":"2024","journal-title":"Hematology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2023.2277674","article-title":"Understanding triple-negative myeloproliferative neoplasms: Pathogenesis, clin-ical features, and management","volume":"65","author":"Tharakan","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e7123","DOI":"10.1002\/cam4.7123","article-title":"Clinical laboratory characteristics and gene mutation spectrum of Ph-negative MPN patients with atypical JAK2, MPL, or CALR variants","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41417-023-00719-7","article-title":"STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient","volume":"31","author":"Zhang","year":"2024","journal-title":"Cancer Gene Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/962\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:04Z","timestamp":1760031544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["medicina61060962"],"URL":"https:\/\/doi.org\/10.3390\/medicina61060962","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}